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Background-—Ischemia–reperfusion injury following ST-segment–elevation myocardial infarction (STEMI) is a leading determinant
of clinical outcome. In experimental models of myocardial ischemia, succinate accumulation leading to mitochondrial dysfunction
is a major cause of ischemia–reperfusion injury; however, the potential importance and speciﬁcity of myocardial succinate
accumulation in human STEMI is unknown. We sought to identify the metabolites released from the heart in patients undergoing
primary percutaneous coronary intervention for emergency treatment of STEMI.
Methods and Results-—Blood samples were obtained from the coronary artery, coronary sinus, and peripheral vein in patients
undergoing primary percutaneous coronary intervention for acute STEMI and in control patients undergoing nonemergency
coronary angiography or percutaneous coronary intervention for stable angina or non-STEMI. Plasma metabolites were analyzed by
targeted liquid chromatography and mass spectrometry. Metabolite levels for coronary artery, coronary sinus, and peripheral vein
were compared to derive cardiac and systemic release ratios. In STEMI patients, cardiac magnetic resonance imaging was
performed 2 days and 6 months after primary percutaneous coronary intervention to quantify acute myocardial edema and ﬁnal
infarct size, respectively. In total, 115 patients undergoing acute STEMI and 26 control patients were included. Succinate was the
only metabolite signiﬁcantly increased in coronary sinus blood compared with venous blood in STEMI patients, indicating cardiac
release of succinate. STEMI patients had higher succinate concentrations in arterial, coronary sinus, and peripheral venous blood
than patients with non-STEMI or stable angina. Furthermore, cardiac succinate release in STEMI correlated with the extent of acute
myocardial injury, quantiﬁed by cardiac magnetic resonance imaging.
Conclusion-—Succinate release by the myocardium correlates with the extent of ischemia. ( J Am Heart Assoc. 2018;7:e007546.
DOI: 10.1161/JAHA.117.007546.)
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A cute ST-segment–elevation myocardial infarction(STEMI) is a leading cause of cardiovascular death
worldwide and remains the primary cause for the
development of chronic heart failure.1 Immediate primary
percutaneous coronary intervention (PPCI) reduces infarct
size by reopening the occluded artery; however, myocardial
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injury caused by subsequent ischemia–reperfusion injury (IRI)
remains a major clinical problem, leading to increased infarct
size, arrhythmias, and heart failure. There are no clinical
treatments to prevent or treat IRI.
Our group recently showed that mitochondrial respiratory
chain function is impaired during ischemia, leading to an
increase in the citric-acid-cycle intermediate succinate through
reversal of succinate dehydrogenase. On reperfusion, restora-
tion of forward succinate dehydrogenase activity leads to the
rapid oxidation of succinate into fumarate and, ultimately, to
the production of damaging reactive oxygen species by reverse
electron transport at mitochondrial complex I.2 This work
suggests that succinate accumulation could be a speciﬁc
metabolic signature of the extent of ischemia and a potential
therapeutic target in limiting IRI.2
Until now, these ﬁndings have been demonstrated only in
animal models of ischemia–reperfusion; whether there is
increased myocardial production of succinate in humans
during acute STEMI is unknown.
In this study, we performed a comprehensive analysis of
bloodmetabolites in STEMI patients and found that succinate is
released by the myocardium into the blood. We also found that
succinate release correlated with the extent of acute myocar-
dial ischemic injury, quantiﬁed by T2-weighted cardiac mag-
netic resonance imaging (cMRI). Our results suggest that
succinate is an early marker of ischemic injury in STEMI
patients.
Methods
The data and analytic methods will be made available to other
researchers for purposes of reproducing the results. The data
are available from the corresponding author upon reasonable
request.
Patients
Patients undergoing emergency PPCI for STEMI were recruited
as part of the OxAMI (Oxford Acute Myocardial Infarction)
study. Diagnosis of STEMI was established on the basis of chest
pain, ST-segment elevation of 0.2 mV in at least 2 contiguous
leads on ECG, and TIMI (Thrombolysis in Myocardial Infarction)
grade 0 ﬂow on initial angiography. Verbal consent for
participation was obtained at the time of PPCI.3 Informed
written consent for continued participation was obtained within
the following 24 hours. The comparison population comprised
patients referred for nonemergency coronary angiography or
percutaneous coronary intervention (PCI) for angina or non-
STEMI (NSTEMI). The study protocols and consent processes
were approved by the local research ethics committee (REC
numbers 08/H0603/41 and 11/SC/0397).
Angiography and PCI
Patients with STEMI received aspirin (300 mg) and clopidogrel
(600 mg) or ticagrelor (180 mg) loading before PPCI and were
treated with intravenous bivalirudin and/or unfractionated
heparin during the procedure. Coronary intervention was
performed using a 6F guiding catheter via the radial artery.
Epicardial coronary reperfusion was established using a
thrombus aspiration catheter and/or balloon before dilatation.
All patients received intracoronary glyceryl trinitrate (0.5–2 mg
total over a variable number of boluses). The culprit lesion was
treated with drug-eluting stent deployment and dual antiplate-
let therapy with aspirin and clopidogrel or ticagrelor for
12 months. Patients undergoing nonemergency angiography
or PCI were treated with aspirin and clopidogrel and received
unfractionated heparin (70 IU/kg) before PCI. Appropriate
secondary prevention commenced with statins, angiotensin-
converting enzyme inhibitors, and beta blockers. The coronary
sinus (CS) was catheterized using a 6F catheter via the femoral
or antecubital vein. Blood from the CS, coronary artery (CA),
and peripheral vein (PV) was sampled for metabolite quantiﬁ-
cation immediately after stent deployment. Blood oxygen
Clinical Perspective
What Is New?
• Mitochondrial dysfunction is a feature of ischemia–reperfu-
sion injury, leading to generation of reactive oxygen species.
• In experimental models of ischemia–reperfusion, mitochon-
drial reactive oxygen species generation is mediated by
reversal of succinate dehydrogenase, leading to succinate
accumulation.
• On reperfusion, restoration of succinate dehydrogenase
activity leads to rapid succinate oxidation, causing reactive
oxygen species generation by reverse electron transport at
mitochondrial complex I.
• By measuring the concentration of succinate in coronary
artery and coronary sinus blood in patients immediately after
percutaneous coronary intervention for ST-segment–eleva-
tion myocardial infarction, this study shows that increased
myocardial production of succinate is a feature of acute ST-
segment–elevation myocardial infarction in humans.
What Are the Clinical Implications?
• The observation of myocardial succinate release and the
association between myocardial succinate release and area
at risk, quantiﬁed by cardiac magnetic resonance imaging,
suggests that succinate accumulation could be a speciﬁc
metabolic signature of the extent of ischemia.
• Targeting mitochondrial dysfunction causing myocardial
succinate accumulation may be a potential therapeutic
target in limiting ischemia-reperfusion injury in patients with
ST-segment–elevation myocardial infarction.
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tension was measured in CS, CA, and PV blood samples to
validate sampling locations; samples were included in the
analysis only if blood oxygen tension in CS bloodwas lower than
blood oxygen tension in PV blood. All samples were immedi-
ately centrifuged to obtain platelet-poor plasma, conﬁrmed by
platelet count,4 and stored at 80°C.
cMRI Quantiﬁcation of Area At Risk and Infarct
Size
STEMI patients underwent cMRI within 48 hours of admission
and 6 months later. Left ventricular function and myocardial
injury were assessed in matching short-axis slices using
steady-state free precession, T2-weighted, and late gadolin-
ium enhancement imaging after the administration of
0.1 mmol/kg contrast agent (Dotarem [gadoterate meglu-
mine]; Guerbet Groupe), as described previously.5,6
Metabolite Quantiﬁcation and Analysis
Quantiﬁcation of metabolites was performed using liquid
chromatography coupled to mass spectrometry analysis, as
described previously.2 Before liquid chromatography–mass
spectrometry, plasma was thawed and centrifuged at
16 000g for 15 minutes at 4°C. After liquid chromatography,
the mass spectrometer (Thermo QExactive Orbitrap) was
operated in full mass spectrometry and polarity switching
mode. Samples were randomized to avoid bias due to
machine drift. Spectra were analyzed using XCalibur Qual
Browser and XCalibur Quan Browser software (Thermo
Scientiﬁc) by referencing to an internal library of compounds.
Absolute quantiﬁcation of succinate was performed by
interpolation of the corresponding standard curve obtained
from serial dilutions of a reference standard that was run with
the same batch of samples.
Cardiac release of metabolites was assessed by simulta-
neous sampling of CS and CA blood. This sampling protocol
allowed computation of the cardiac release ratio for each
metabolite by calculating the ratio of the difference between
CS concentration and CA concentration to the CA concen-
tration ð½CS½CA½CA Þ for each metabolite and each patient.
Similarly, the systemic release ratio was calculated using the
PV concentration of the considered metabolite and the CA
concentration ð½PV½CA½CA Þ. Metabolites with signiﬁcantly
higher cardiac release ratios compared with systemic release
ratios were assumed to be speciﬁcally released by the heart.
Statistical Analyses
All clinical parameters and metabolite concentrations were
expressed as meanSEM. Release ratios of metabolites were
expressed as median and interquartile range.
The Wilcoxon–Mann–Whitney test was used for statistical
comparison of positive release ratios for a given metabolite in
STEMI patients. The Kruskal–Wallis test followed by pairwise
multiple comparison with the Dunn method was used for
comparison of succinate concentration between groups.
Association between succinate values and myocardial
edema measured 2 days after PCI or infarct size measured
6 months after PCI were made by a nonparametric Spearman
rank correlation test. We also measured the association with
myocardial edema using a multiple linear regression model
with succinate, sex, body surface area, and age as indepen-
dent variables. In the latter, no signiﬁcant effect was found,
which suggests no confounding factors.
A P value of <0.05 was considered statistically signiﬁcant.
All statistical analyses have performed using Systat 13.1
software (Systat Software).
Results
In total, 115 patients undergoing emergency PCI for STEMI
were recruited between September 2012 and July 2015. The
median age was 64 years, and 97 (79.5%) of the patients
were male (Table). The culprit vessel was the right CA in 55
patients (48%), the left anterior descending artery in 47
patients (41%), and the circumﬂex artery in 13 patients (11%).
Median time between pain onset and procedure was
8629 minutes. Forty-four patients underwent cMRI within
2 days after PPCI. Among them, 26 presented with left
coronary infarct (patients with culprit left anterior descending
or circumﬂex artery).
Twenty-six patients undergoing nonemergency coronary
angiography were recruited as a comparison group. These
patients had demographic characteristics similar to the STEMI
patients. Among them, 9 underwent PCI for NSTEMI or
unstable angina and 11 for stable angina. Six of these PCI
procedures (30%) were performed for plaque lesion in the
right CA. Six patients underwent diagnostic angiography
alone, without PCI.
Succinate Is Released From the Myocardium in
STEMI Patients
Blood samples from the CA, CS, and PV were collected within
10 minutes of PPCI, and metabolite levels were measured
using liquid chromatography–mass spectrometry. For each
metabolite in STEMI patients, the cardiac release ratio was
calculated from CA and CS concentrations (Figure 1). A
positive cardiac release ratio indicates that the metabolite is
released into the veins by the upstream myocardial tissue,
which is dominated by cardiomyocytes but also includes
arterial and venous endothelium and other cells, whereas
negative release ratios indicate that the metabolite is
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Table. Patient Characteristics
General Characteristics
STEMI Patients
n=115
Angina or NSTEMI Patients
n=26
P Values Between
Groups
Age, y, mean (range) 64 (36–88) 65 (37–84) 0.719
Male 92 (80) 22 (84.6) 0.792
Comorbidities
Diabetes mellitus 11 (9.0) 5 (19.2) 0.289
Oral medication 7 (6.1) 5 (19.2) 0.075
Insulin 2 (2.5) 1 (0.4) 0.936
New diagnosis 1 (0.9) 0 (0) 0.414
Chronic kidney disease 1 (0.9) 0 (0) 0.414
Smoking
Current smoker 42 (36.5) 4 (15.4) 0.081
Ex-smoker 42 (36.5) 14 (53.8) 0.159
Lung disease 12 (10.4) 0 (0) 0.183
Coronary artery disease 48 (41.7) 18 (69.2) 0.020
Previous MI 6 (5.2) 10 (38.5) <0.001
Previous PCI 7 (6.1) 9 (34.6) <0.001
Previous CABG 0 (0.0) 3 (11.5) 0.003
Hypercholesterolemia 37 (32.2) 18 (69.2) <0.001
Hypertension 46 (40.0) 16 (61.5) 0.075
Peripheral vascular disease 1 (0.9) 1 (0.4) 0.81
Cerebrovascular disease 3 (2.6) 4 (11.5) 0.027
Valvular heart disease 0 (0.0) 0 (0) 
Heart failure 0 (0.0) 0 (0) 
Drugs on admission*
None 35 (30.4) 5 (19.2) 0.366
Aspirin 10 (8.7) 17 (65.4) <0.001
Clopidogrel 0 (0.0) 11 (42.3) <0.001
ACE inhibitor 20 (17.4) 20 (76.9) <0.001
Angiotensin receptor blocker 7 (6.1) 12 (46.1) <0.001
Beta blocker 11 (9.6) 3 (11.5) 0.851
Calcium channel blocker 18 (15.7) 14 (53.8) <0.001
Diuretic 8 (7.0) 5 (19.2) 0.114
Insulin 3 (2.6) 4 (15.4) 0.027
Oral hypoglycemic 7 (6.1) 1 (0.4) 0.981
Proton pump inhibitor 25 (21.7) 5 (19.2) 0.986
Statin 25 (21.7) 10 (38.5) 0.126
Procedural drugs
Unfractionated heparin 35 (30.4) 5 (19.2) 0.366
Bivalirudin 97 (84.4) 0 (0) <0.001
Data are shown as n (%) except as noted. Clinical details of patients with STEMI and the comparison group with NSTEMI or angina. Chronic kidney disease was deﬁned as baseline
creatinine value >200 lmol/L. ACE indicates angiotensin-converting enzyme; CABG, coronary artery bypass grafting; MI, myocardial infarction; NSTEMI, non-ST-segment–elevation
myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-segment–elevation myocardial infarction.
*The term drugs on admission refers to medications taken regularly before admission and does not include loading doses of aspirin and ticagrelor/clopidogrel before PCI.
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consumed from the blood by the myocardial tissue. We also
calculated the systemic release ratio, using the PV and CA
concentrations of each metabolite, to evaluate nonspeciﬁc
changes in metabolite levels. Strikingly, succinate was the
only metabolite that exhibited a signiﬁcantly higher cardiac
release ratio compared with the systemic release ratio
(Figure S1), suggesting a speciﬁc release of succinate by
the heart during emergency PCI in STEMI patients.
We then compared the succinate concentrations in the
blood between patients with STEMI and those with angina or
NSTEMI (Figure 2A). In STEMI patients, blood succinate
concentration was signiﬁcantly increased in CA, CS, and PV,
compared with patients with angina. Furthermore, succinate
concentration was signiﬁcantly higher in CA and CS blood in
STEMI patients compared with NSTEMI patients. The greatest
difference in succinate concentrations was observed in CS
blood, with mean succinate concentrations of 1.380.14,
1.590.14, and 2.730.11 lmol/L in patients with angina,
NSTEMI, and STEMI, respectively (P<0.05). The increase in CS
succinate was seen only in patients undergoing PPCI; there
was no effect of either diagnostic angiography or nonemer-
gency PCI on succinate concentration (Figure 2B).
CS Succinate Concentration in STEMI Correlates
With the Extent of Acute Myocardial Ischemic
Injury
We next tested the relationship between myocardial succi-
nate release and the extent of acute IRI, using cMRI
quantiﬁcation of acute myocardial edema after PPCI. Because
the drainage of the right CA territory into the CS is variable,
we analyzed STEMI patients with left anterior descending or
circumﬂex CA occlusions. Performed within 2 days of PPCI,
cMRI revealed a mean extent of acute myocardial edema of
37.316.2% of left ventricular mass. CS succinate concen-
tration was signiﬁcantly correlated with acute myocardial
edema quantiﬁed by cMRI (Spearman R=0.43, P<0.05;
Figure 3). In contrast, there was no signiﬁcant correlation
between CS succinate concentration and ﬁnal myocardial
infarct size assessed by cMRI 6 months after PPCI (R=0.136;
P=0.08) or with troponin area under the curve (Figure S2),
measured over 48 hours after PPCI, suggesting that myocar-
dial succinate release is a speciﬁc biomarker of acute
myocardial ischemic injury rather than a biomarker of
irreversible myocardial necrosis.
Discussion
We used a metabolomics approach to quantify the changes in
myocardial metabolite release in response to acute IRI in
STEMI patients undergoing emergency PPCI. We analyzed
blood sampled simultaneously from CS, CA, and PV during
PPCI and demonstrated a speciﬁc increase in succinate
release by the ischemic myocardium of STEMI patients
compared with patients undergoing PCI for angina or NSTEMI.
Cardiac succinate release leads to a signiﬁcantly higher blood
succinate concentration in STEMI patients compared with
patients with less severe ischemia (angina or NSTEMI).
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Figure 1. Speciﬁc release of metabolites from the heart in ST-
segment–elevation myocardial infarction. Metabolites were quan-
tiﬁed by liquid chromatography and mass spectrometry in paired
samples of coronary artery (CA) and coronary sinus (CS) blood.
The cardiac release ratio was calculated from the difference
between CA and CS concentration, divided by the CA concentra-
tion. Each bar represents the median and interquartile range of
the cardiac release ratio. Positive values represent a release of
the metabolite into the blood by the heart, whereas negative
values represent consumption of the metabolite from the blood by
the heart. For each metabolite, cardiac release ratio has been
compared with systemic release ratio (presented in Figure S1).
*P<0.05 for cardiac vs systemic release ratio.
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Furthermore, we demonstrated that succinate concentration
in CS blood correlates with the early extent of myocardial
edema measured by cMRI, as a marker of acute ischemic
injury.
We previously reported that cardiac IRI in rodent models is
associated with an alteration of the mitochondrial respiratory
chain leading to the speciﬁc accumulation of succinate in the
heart.2 Other experimental studies also showed cellular
accumulation of succinate during hypoxia in rabbits7 and on
ischemia in the isolated, perfused mouse heart.8 In the
current study, we report that cardiac-speciﬁc release of
succinate is a feature of human IRI in patients undergoing
emergency PPCI for STEMI, most likely reﬂecting succinate
accumulation during ischemia and subsequent release from
ischemic myocardial tissue following reperfusion. The large
metabolite analysis that we performed in this study also
showed interesting variations in other metabolites and
especially in the release ratios for glutamate and acetoac-
etate. For these 2 metabolites, the release ratio was lower,
albeit not signiﬁcantly decreased, compared with the sys-
temic release ratio.
Consistent with a role for succinate in IRI, we demon-
strated that succinate levels in the CS are associated with the
extent of the acute ischemic injury, as quantiﬁed by the “area
at risk” delineated by the area of acute myocardial ischemia
on cMRI T2-weighted imaging. Furthermore, the observation
that NSTEMI is associated with lower levels of ischemia and
reduced infarct size compared with STEMI9 is consistent with
our ﬁndings that myocardial succinate release is lower in
NSTEMI patients than in STEMI patients. Another reason for
reduced myocardial succinate release was that NSTEMI
3
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Figure 2. Blood succinate concentrations in patients with
Angina, NSTEMI or STEMI. Absolute succinate concentrations in
coronary artery, coronary sinus, and peripheral vein blood were
compared for patients with angina, NSTEMI, or STEMI (A) and for
patients undergoing coronary angiography without PCI, PCI for
angina or NSTEMI, or PPCI for STEMI (B). A, *P<0.05 vs patients
with angina; †P<0.05 vs NSTEMI patients for the corresponding
sampling site. B, *P<0.05 vs patients with PCI patients; †P<0.05
vs no-PCI patients for the corresponding sampling site. NSTEMI
indicates non–ST-segment–elevation myocardial infarction; PCI,
percutaneous coronary intervention; PPCI, primary percutaneous
coronary intervention; STEMI, ST-segment–elevation myocardial
infarction.
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Figure 3. Correlation between coronary sinus succinate con-
centration and acute myocardial edema. Acute ischemia–reper-
fusion injury was quantiﬁed by T2 magnetic resonance imaging of
edema within 2 days after primary percutaneous coronary
intervention in patients with ST-segment–elevation myocardial
infarction due to left anterior descending or circumﬂex coronary
artery occlusions. The extent of left ventricular (LV) myocardial
edema, expressed as a percentage of LV mass, was correlated
with coronary sinus succinate concentration.
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patients underwent PCI (and, therefore, blood sampling)
within 72 hours of hospital admission, which allowed time for
succinate accumulation to resolve, unlike the STEMI patients,
who underwent emergency PCI on arrival. Only 1 previous
study described succinate concentration in PVs of myocardial
infarction patients10. In that study, the peripheral blood
succinate concentration was assessed in only 3 patients with
acute myocardial infarction and was shown to be signiﬁcantly
higher than in healthy volunteers.
In STEMI patients with left anterior descending or circum-
ﬂex CA occlusions, we found that succinate concentration in
the CS correlated with the extent of myocardial edema on
cMRI. Although myocardial edema as a marker of IRI remains
controversial,11 the early edema quantiﬁed by cMRI has been
shown to correlate well with the size of the area at risk after
myocardial infarction.12,13 These results suggest that succi-
nate is associated with the extent of myocardial IRI in STEMI
patients.
In our study, we did not detect any correlation between
succinate release and the ﬁnal infarct size, quantiﬁed
6 months after STEMI by late gadolinium enhancement on
cMRI. Furthermore, myocardial succinate release did not
correlate with troponin area under the curve in the 48 hours
after STEMI, as a marker of myocardial necrosis. Thus,
myocardial succinate release is a marker of acute IRI rather
than irreversible myocardial injury or ﬁnal infarct size.
There was no correlation between ﬁnal infarct size and
myocardial succinate release, which may be due to the
undeﬁned relationship between succinate released from
myocardial cells into CS blood and the level of succinate
that is retained by myocardial cells. In addition, ﬁnal infarct
size is determined by the extent of ischemia and the salvage
of the myocardium by PPCI and other therapies. The
discordance between the magnitude of acute IRI (area at
risk) and the ﬁnal infarct size is used to estimate the “salvage
index” as an indicator of the effectiveness of coronary
reperfusion. Consequently, infarct size at 6 months depends
not only on the magnitude of the initial IRI but also on the
efﬁcacy and timing of the reperfusion therapy and other
determinants of late myocardial remodeling after STEMI.14
Our study has several potential limitations. First, as
demonstrated in animal models, tissue succinate levels return
to baseline within the ﬁrst few minutes of reperfusion.2 In
PPCI patients, the timing between the onset of reperfusion
and subsequent blood sampling is not well deﬁned, given
biological heterogeneity in the pathophysiology of ischemia–
reperfusion in STEMI, for example, because of distal “no-
reﬂow,” side branch occlusion, or embolization. Technical
considerations that impose variability and delay could also
contribute to variation in succinate concentration. Neverthe-
less, we enriched the biological signal through (1) careful
selection of STEMI patients with an occluded CA at
presentation and matched blood sampling immediately after
reperfusion and stent placement and (2) rigorous quality
control to ensure high ﬁdelity and consistent CS blood
sampling.
We compared STEMI patients with NSTEMI and stable
angina patients. In all of these groups, a certain degree of
ischemia is expected. Even so, we found several differences
between groups regarding the history of cardiovascular
disease, cerebrovascular disease, and hypercholesterolemia.
Even if those ﬁndings do not interact directly with the
ischemic burden or succinate release, they could represent a
limitation of the statistical analysis. In addition, the subse-
quent differences in anticoagulant and antiplatelet drugs
administered could, in principle, interact with succinate levels
and thereby contribute to differences between groups,
although we note that there are no reports of such
confounding effects in the literature. Because of ethical
considerations, blood samples of the CS and aortic root could
not be obtained from healthy volunteers; therefore, the level
of succinate under these conditions is unknown. However, in
a study that investigated the role of succinate in cardiac
hypertrophy, the authors were unable to detect succinate in
peripheral blood,10 suggesting that the succinate concentra-
tion in the CS and aortic root is likely to be low in healthy
participants.
Conclusion
We demonstrated that succinate is released from the
myocardium into the blood during acute STEMI and that
myocardial succinate release correlates with the severity of
IRI. Although CS concentration of succinate relates directly to
cardiac succinate release, PV concentration of succinate may
provide a more accessible biomarker of IRI in STEMI patients.
These data show that the accumulation of succinate during
ischemia, previously shown in rodents, also occurs in humans
and thus suggests novel therapeutic targets for cardioprotec-
tive pharmacological strategies.
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Figure S1. Systemic release of metabolites by peripheral tissue in blood. Each bar 
represents the median and interquartile range of the systemic release ratio. This ratio is 
the difference between concentrations in peripheral vein and coronary artery, divided by 
the coronary artery concentration. Positive values represent a release of metabolite in 
the blood and negative values represent a consumption of the metabolite.  
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Figure S2. Correlation between succinate concentration in the coronary sinus succinate 
and the area under the curve of troponin release during 48 hours post STEMI.  
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